BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22791814)

  • 1. The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells.
    Tseng HY; Chen LH; Ye Y; Tay KH; Jiang CC; Guo ST; Jin L; Hersey P; Zhang XD
    Carcinogenesis; 2012 Oct; 33(10):1871-81. PubMed ID: 22791814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
    Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response.
    Chen LH; Jiang CC; Kiejda KA; Wang YF; Thorne RF; Zhang XD; Hersey P
    Carcinogenesis; 2007 Nov; 28(11):2328-36. PubMed ID: 17652336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
    Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
    Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
    Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
    Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
    Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
    Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8.
    Kurita S; Higuchi H; Saito Y; Nakamoto N; Takaishi H; Tada S; Saito H; Gores GJ; Hibi T
    Cancer Sci; 2010 Jun; 101(6):1431-9. PubMed ID: 20398055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
    Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
    Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
    Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
    Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
    Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis.
    Yoshida T; Shiraishi T; Horinaka M; Nakata S; Yasuda T; Goda AE; Wakada M; Mizutani Y; Miki T; Nishikawa A; Sakai T
    Cancer Sci; 2007 Sep; 98(9):1417-23. PubMed ID: 17645780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2.
    Li J; Anderson MG; Tucker LA; Shen Y; Glaser KB; Shah OJ
    Cell Death Differ; 2009 Mar; 16(3):498-511. PubMed ID: 19079141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
    Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
    Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
    Horinaka M; Yoshida T; Nakata S; Shiraishi T; Tomosugi M; Yoshikawa S; Wakada M; Sakai T
    Cancer Sci; 2012 Feb; 103(2):282-7. PubMed ID: 22077238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY; Yue P; Hong WK; Lotan R
    Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.